SCHEMBL7165261

SCHEMBL7165261

NC(=O)CN1C(=O)C=CC1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 2/20 0.50
GSK3B P49841 2/20 0.50
RAB9A P51151 2/20 0.46
CYP2C19 P33261 2/20 0.44
MGLL Q99685 6/20 0.44
ALDH1A1 P00352 3/20 0.44
FAAH O00519 3/20 0.44
LMNA P02545 2/20 0.44
MAPT P10636 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
BLM P54132 2/20 0.44
GMNN O75496 1/20 0.44
THPO P40225 1/20 0.44
PMP22 Q01453 1/20 0.44
KMT2A Q03164 1/20 0.43
HPGD P15428 2/20 0.42
HSP90AA1 P07900 1/20 0.42
TLR9 Q9NR96 1/20 0.42
TP53 P04637 1/20 0.42
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL515800 0.77 PTGS1 (0.52) GSK3AGSK3BRAB9ACYP2C19MGLL
SCHEMBL255340 0.76 MGLL (0.52) GSK3AGSK3BRAB9ACYP2C19MGLL
Hydrochloric Acid SCHEMBL28991159 0.75 PTGS1 (0.50) GSK3AGSK3BRAB9ACYP2C19MGLL
SCHEMBL11955666 0.75 GSK3A (0.55) GSK3AGSK3BRAB9ACYP2C19MGLL
SCHEMBL28353956 0.75 GSK3A (0.50) GSK3AGSK3BRAB9ACYP2C19MGLL
SCHEMBL8010430 0.75 GSK3A (0.50) GSK3AGSK3BRAB9ACYP2C19MGLL
SCHEMBL8738193 0.75 GSK3A (0.46) GSK3AGSK3BRAB9ACYP2C19MGLL
SCHEMBL1704532 0.75 MGLL (0.62) GSK3AGSK3BRAB9ACYP2C19MGLL
SCHEMBL29995038 0.73 GSK3A (0.48) GSK3AGSK3BRAB9ACYP2C19MGLL
SCHEMBL1103791 0.73 GSK3A (0.48) GSK3AGSK3BRAB9ACYP2C19MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025067221-A1 AURISTATIN DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF 上海齐鲁制药研究中心有限公司 2025-04-03 WO disclosed
WO-2024020164-A2 GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF FIREFLY BIO, INC. (US) 2024-01-25 WO disclosed
US-20230038373-A1 STABILE CONJUGATE GLYKOS BIOMEDICAL OY (FI) 2023-02-09 US disclosed
WO-2023280227-A2 LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME PROFOUNDBIO US CO. (US) 2023-01-12 WO disclosed
CN-113087650-A Preparation method of 2-maleimidoacetic acid N-hydroxysuccinimide ester 苏州昊帆生物股份有限公司 2021-07-09 CN disclosed
WO-2021110860-A1 REACTIVE CONJUGATES DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) 2021-06-10 WO disclosed
CN-105669855-B A kind of 18Method for rapidly marking Cys-Annexin V by using F and application thereof 江苏省原子医学研究所 2020-02-11 CN disclosed
WO-2017060322-A2 PTEFB-INHIBITOR-ADC BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-04-13 WO disclosed
CN-105669855-A Method for rapidly marking Cys-Annexin V through <18>F and application of method 江苏省原子医学研究所 2016-06-15 CN disclosed
EP-2668039-B1 A LITHOGRAPHIC PRINTING PLATE PRECURSOR AGFA GRAPHICS NV (BE) 2015-06-03 EP disclosed
EP-0742903-B1 PIPERIDINE ANALOGS AND CONJUGATES OF PROCAINAMIDE AND NAPA ROCHE DIAGNOSTICS CORP (US) 2002-01-16 EP disclosed
EP-0429611-B1 AMINOALKYL MALEIMIDES AND HAPTENE AND ANTIGEN DERIVATIVES THEREOF AND CONJUGATES WITH PEPTIDES OR PROTEINS ROCHE DIAGNOSTICS GMBH (DE) 2001-02-28 EP disclosed
EP-0742903-A4 PIPERIDINE ANALOGS AND CONJUGATES OF PROCAINAMIDE AND NAPA ROCHE DIAGNOSTICS CORP (US) 2000-04-05 EP disclosed
US-5798276-A DETECTING COMPLEMENTARY MEMBER OF SPECIFIC BINDING PAIR USING FLUORESCENT CONJUGATE MOLECULAR PROBES, INC. (US) 1998-08-25 US disclosed
US-5595741-A Aminoalkylmaleimides and hapten and antigen derivatives derived therefrom as well as conjugates with peptides or proteins BOEHRINGER MANNHEIM GMBH (DE) 1997-01-21 US disclosed
EP-0742903-A1 PIPERIDINE ANALOGS AND CONJUGATES OF PROCAINAMIDE AND NAPA BOEHRINGER MANNHEIM CORPORATION (US) 1996-11-20 EP disclosed
US-5525474-A IMMUNOASSAY; LINKING THE HAPTENIC DRUG VIA ITS MALEIMIDE MOIETY AND A SULFHYDRYL BRIDGE TO AN IMMUNOGENIC CARRIER TO STIMULATE ANTIBODIES BOEHRINGER MANNHEIM CORPORATION (US) 1996-06-11 US disclosed
WO-1995020763-A1 PIPERIDINE ANALOGS AND CONJUGATES OF PROCAINAMIDE AND NAPA BOEHRINGER MANNHEIM CORPORATION (US) 1995-08-03 WO disclosed
EP-0429611-A1 AMINOALKYL MALEIMIDES AND HAPTENE AND ANTIGEN DERIVATIVES THEREOF AND CONJUGATES WITH PEPTIDES OR PROTEINS Roche Diagnostics GmbH (DE) 1991-06-05 EP disclosed
WO-1990015798-A1 AMINOALKYL MALEIMIDES AND HAPTENE AND ANTIGEN DERIVATIVES THEREOF AND CONJUGATES WITH PEPTIDES OR PROTEINS BOEHRINGER MANNHEIM GMBH (DE) 1990-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230038373-A1 STABILE CONJUGATE CD2, TTL, DDOST GSK3A 3746/4885GSK3B 3998/4885RAB9A 998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.